10x Genomics Settles Patent Dispute With Bruker

10x Genomics, Inc. (NASDAQ:TXG) is among the 11 Best Genomics Stocks to Buy According to Hedge Funds. It has announced a global settlement agreement with Bruker Corporation, which resolves all outstanding patent litigation between the two firms.

10x Genomics Settles Patent Dispute With Bruker.

A team of medical professionals in surgical scrubs analysing research data in a laboratory.

As per the agreement, from Q3 2025 to Q2 2026, Bruker will pay 10x Genomics, Inc. (NASDAQ:TXG) $68 million in equal quarterly installments. Furthermore, Bruker will pay continuous royalties on sales of spatial biology products for the duration of the licensed patents. Global patent cross-licenses and the termination of all legal actions in the United States, Germany, and the European Unified Patent Court are part of the settlement.

10x Genomics, Inc. (NASDAQ:TXG), a leader in single-cell and spatial biology, pointed out the need for intellectual property protection to promote scientific innovation. CEO Serge Saxonov regarded the outcome as a validation of the company’s vision and dedication to innovation.

Eric Whitaker, Chief Legal Officer, noted the robustness of the firm’s IP portfolio and its fundamental function in spatial biology. The settlement makes it possible to keep funding upcoming innovations.

While we acknowledge the potential of TXG as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025.

Disclosure. None.